469 related articles for article (PubMed ID: 33278287)
1. Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
Kurnit KC; Fleming GF; Lengyel E
Obstet Gynecol; 2021 Jan; 137(1):108-121. PubMed ID: 33278287
[TBL] [Abstract][Full Text] [Related]
2. Management and Treatment of Recurrent Epithelial Ovarian Cancer.
Armbruster S; Coleman RL; Rauh-Hain JA
Hematol Oncol Clin North Am; 2018 Dec; 32(6):965-982. PubMed ID: 30390768
[TBL] [Abstract][Full Text] [Related]
3. Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.
Buechel M; Herzog TJ; Westin SN; Coleman RL; Monk BJ; Moore KN
Ann Oncol; 2019 May; 30(5):721-732. PubMed ID: 30887020
[TBL] [Abstract][Full Text] [Related]
4. First-Line Management of Advanced High-Grade Serous Ovarian Cancer.
Mahmood RD; Morgan RD; Edmondson RJ; Clamp AR; Jayson GC
Curr Oncol Rep; 2020 Jun; 22(6):64. PubMed ID: 32494876
[TBL] [Abstract][Full Text] [Related]
5. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Alvarez Secord A; O'Malley DM; Sood AK; Westin SN; Liu JF
Gynecol Oncol; 2021 Aug; 162(2):482-495. PubMed ID: 34090705
[TBL] [Abstract][Full Text] [Related]
6. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
7. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
8. SEOM clinical guideline in ovarian cancer (2020).
Redondo A; Guerra E; Manso L; Martin-Lorente C; Martinez-Garcia J; Perez-Fidalgo JA; Varela MQ; Rubio MJ; Barretina-Ginesta MP; Gonzalez-Martin A
Clin Transl Oncol; 2021 May; 23(5):961-968. PubMed ID: 33515422
[TBL] [Abstract][Full Text] [Related]
9. Advances in ovarian cancer therapy.
Cortez AJ; Tudrej P; Kujawa KA; Lisowska KM
Cancer Chemother Pharmacol; 2018 Jan; 81(1):17-38. PubMed ID: 29249039
[TBL] [Abstract][Full Text] [Related]
10. Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
Lheureux S; Braunstein M; Oza AM
CA Cancer J Clin; 2019 Jul; 69(4):280-304. PubMed ID: 31099893
[TBL] [Abstract][Full Text] [Related]
11. Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
Schettino C; Musacchio L; Bartoletti M; Chiodini P; Arenare L; Baldassarre G; Califano D; Capoluongo E; Costi MP; D'Incalci M; Marchini S; Mezzanzanica D; Normanno N; Scala S; Greggi S; Perrone F; Pignata S
Int J Gynecol Cancer; 2022 Jun; 32(6):799-803. PubMed ID: 35318277
[TBL] [Abstract][Full Text] [Related]
12. Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions.
Vetter MH; Hays JL
Clin Ther; 2018 Mar; 40(3):361-371. PubMed ID: 29482922
[TBL] [Abstract][Full Text] [Related]
13. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Kurnit KC; Coleman RL; Westin SN
Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
[TBL] [Abstract][Full Text] [Related]
14. Germline and somatic testing for ovarian Cancer: An SGO clinical practice statement.
Gressel GM; Frey MK; Norquist B; Senter L; Blank SV; Urban RR
Gynecol Oncol; 2024 Feb; 181():170-178. PubMed ID: 38215513
[TBL] [Abstract][Full Text] [Related]
15. Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
Manning-Geist BL; Chi DS; Long Roche K; Zivanovic O; Sonoda Y; Gardner GJ; O'Cearbhaill RE; Abu-Rustum NR; Leitao MM
Gynecol Oncol; 2021 Aug; 162(2):345-352. PubMed ID: 34045053
[TBL] [Abstract][Full Text] [Related]
16. Maintenance Therapy in the Treatment of Recurrent Epithelial Ovarian Cancer.
Gnade C; McDonald ME
Clin Obstet Gynecol; 2020 Mar; 63(1):86-91. PubMed ID: 31855903
[TBL] [Abstract][Full Text] [Related]
17. Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.
Chan JK; Liang SY; Kapp DS; Chan JE; Herzog TJ; Coleman RL; Monk BJ; Richardson MT
Gynecol Oncol; 2020 Dec; 159(3):604-606. PubMed ID: 32994055
[No Abstract] [Full Text] [Related]
18. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
Dottino JA; Moss HA; Lu KH; Secord AA; Havrilesky LJ
Obstet Gynecol; 2019 Apr; 133(4):795-802. PubMed ID: 30870286
[TBL] [Abstract][Full Text] [Related]
19. State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer.
Singh N; Badrun D; Ghatage P
Expert Opin Pharmacother; 2020 Sep; 21(13):1579-1590. PubMed ID: 32552175
[TBL] [Abstract][Full Text] [Related]
20. An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer.
de Bree E; Michelakis D
Expert Opin Pharmacother; 2020 Aug; 21(12):1479-1492. PubMed ID: 32486865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]